<< Dettli | Index | Drugbank >>
Dissertation "Drug-Drug Interactions in the Hospital"
Priska von Bach
- http://edoc.unibas.ch/653/1/DissB_8002.pdf
- Seite 78: Although our evaluation showed that Pharmavista provides high sensitivity and sophisticated information about DDIs (mechanism and clinical management) [19], some improvement is desirable. For example, pulmonary inhalation of glucocorticoids is not distinguished from systemic use of glucocorticoids, and thus the combination of inhaled glucocorticoid and low-dose aspirin is designated as a moderate pDDI. The same problem is present with diuretic drugs and pulmonary glucocorticoid treatment.
- Seite 99: We can assume that in 50% (during hospitalization) and 46% (at hospital discharge), respectively, of all detected major and moderate pDDIs by Pharmavista, intervention was accepted by the physicians.
- Seite 103: About one third of all moderate pDDIs detected by Pharmavista were deemed to be not clinically relevant. This corresponds well with our evaluation study [18], which revealed a positive predictive value of 0.67 for Pharmavista using Stockley’s drug interactions [32] as a gold standard.
- Seite 127: Our intervention study showed that one third of all moderate pDDIs detected by Pharmavista were deemed not to be clinically relevant.
- Seite 136: For hospitalized patients, 74% of all detected major and moderate pDDIs by Pharmavista were judged as clinically relevant by the pharmacist. 80% of the recommendations were accepted implemented by the physicians.
Dr. Marco Egbring
- Die Literatur sagt was anderes 10 -20%.